Biogen (BUE:BIIB) Other Long Term Assets : ARS1,344,546 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Biogen Other Long Term Assets?

Biogen's other long-term assets for the quarter that ended in Mar. 2024 was ARS1,344,546 Mil.

Biogen's quarterly other long-term assets declined from Sep. 2023 (ARS638,449 Mil) to Dec. 2023 (ARS604,170 Mil) but then increased from Dec. 2023 (ARS604,170 Mil) to Mar. 2024 (ARS1,344,546 Mil).

Biogen's annual other long-term assets increased from Dec. 2021 (ARS338,781 Mil) to Dec. 2022 (ARS461,976 Mil) and increased from Dec. 2022 (ARS461,976 Mil) to Dec. 2023 (ARS604,170 Mil).

Biogen Other Long Term Assets Historical Data

The historical data trend for Biogen's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Long Term Assets Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

268,078.62

347,370.52

338,781.05

461,976.33

604,169.60

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															512,168.14	555,192.00	638,448.80	604,169.60	1,344,545.77

Biogen Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.